ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use Conference Paper uri icon


MeSH Major

  • Anti-Inflammatory Agents, Non-Steroidal
  • Gastrointestinal Hemorrhage
  • Platelet Aggregation Inhibitors


  • In appropriate patients oral antiplatelet therapy decreases ischemic risks, but this therapy may increase bleeding complications. Of the major bleeding that occurs, the largest proportion is due to GI hemorrhage. Concomitant use of NSAIDs further raises the risk of GI bleeding. Gastroprotection strategies consist of use of PPIs in patients at high risk of GI bleeding and eradication of H. pylori in patients with a history of ulcers. Communication between cardiologists, gastroenterologists, and primary care physicians is critical to weigh the ischemic and bleeding risks in an individual patient who needs antiplatelet therapy but who is at risk for or develops significant GI bleeding. © 2008 by Am. Coll. of Gastroenterology.

publication date

  • November 2008



  • Conference Paper



  • eng

Digital Object Identifier (DOI)

  • 10.1111/j.1572-0241.2008.02216.x

PubMed ID

  • 18853965

Additional Document Info

start page

  • 2890

end page

  • 907


  • 103


  • 11